An aromatase inhibitor (AI) showed efficacy that was superior to that of tamoxifen (TAM) in large-scale randomized clinical trials in breast cancer patients, and AIs are now the most extensively used drugs for postoperative adjuvant therapy for hormone-dependent postmenopausal breast cancer [1, 2]. Here, CYP19A1 is linked to breast cancer.